Join HFSA in promoting the 3rd annual Virtual Heart Failure Patient & Caregiver Day, taking place Saturday, February 12, 2022. #HFPatientDay2022 features interactive educational discussions with leading heart failure experts, a heart-healthy cooking demonstration, an exercise demonstration and more! To register for the event, please click HERE. Registration is complimentary to all heart failure patients, caregivers,
Blog
Woman Vows to “Live Her Best Life” After DCM & Heart Transplant
A 19-year-old mother from Allerton, England was diagnosed with dilated cardiomyopathy and fell very ill when she was pregnant, forcing an early birth via c-section. She received a heart transplant and initially faced complications that kept her in the hospital, but she eventually recovered. Her resolution now is to “live her best life”. Read her whole
Read More… from Woman Vows to “Live Her Best Life” After DCM & Heart Transplant
Natural History Study Seeks Participants with MYBPC3 Genetic Mutation
Tenaya Therapeutics, a biotechnology company committed to discovering, developing, and delivering curative therapies that address the underlying causes of heart disease, is sponsoring a study to better understand pediatric cardiomyopathy due to the MYBPC3 mutation. The MyClimb Natural History Study is designed to collect and evaluate information on the course of cardiomyopathy in children and adolescents <18
Read More… from Natural History Study Seeks Participants with MYBPC3 Genetic Mutation
Living with DCM – A Patient’s Perspective
Learn from 3 DCM patients about their experiences living with DCM: – Daily Activities – Staying Active – Managing Stress and Anxiety
Advancements in Gene Therapy Manufacturing
By creating scientific forums to foster collaboration and creativity, Tenaya Therapeutics has been able to optimize gene therapy manufacturing. Such advancements can help make gene therapy more accessible and affordable for larger patient populations. Read the full article here: https://www.cellandgenecollaborative.com/doc/the-ties-that-bind-engineering-a-cgt-manufacturing-centric-culture-0001
The Latest in DCM therapies in Development – with Tenaya
The latest in DCM therapies in development – with Tenaya Therapeutics
Read More… from The Latest in DCM therapies in Development – with Tenaya
DCMF Webinar: “DCM & Heart Transplant: 3 Patient Stories”
Learn about DCM & Heart Transplant from 3 DCM patients and heart transplant recipients.
Read More… from DCMF Webinar: “DCM & Heart Transplant: 3 Patient Stories”
BAG3 Mutation Discovery & Gene Therapy Development
The following documentary film demonstrates the discovery of the BAG 3 genetic mutation that can cause DCM and the development of the gene therapy that became Renovacor. Please click here to view the video to learn more: https://vimeo.com/173290791
Read More… from BAG3 Mutation Discovery & Gene Therapy Development
November is National Family Health History Month
Genetic research has shown that 20-30% of individuals with DCM may have another affected family member. This is due to family members inheriting the same mutations in the genetic code of one or more genes whose role is key for normal heart muscle function. Genetic testing is now widely available from laboratories. It is recommended
Read More… from November is National Family Health History Month
Unite and be heard at the upcoming Virtual Global Heart Hub Summit!
On the 22nd and 23rd of November, the Global Heart Hub is bringing together the cardiovascular patient community from across the world for its first annual VIRTUAL Unite Summit, aimed at strengthening the voice of those living with heart disease. Date: Mon/Tues – November 22nd & 23rd (two half-day sessions) Time: 15:00 – 18:00 CET (Click here to check the
Read More… from Unite and be heard at the upcoming Virtual Global Heart Hub Summit!